[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK3111950T3 - Fremgangsmåder og sammensætninger relateret til glucocorticoidreceptorantagonisme og prostatacancer - Google Patents

Fremgangsmåder og sammensætninger relateret til glucocorticoidreceptorantagonisme og prostatacancer Download PDF

Info

Publication number
DK3111950T3
DK3111950T3 DK16183642.4T DK16183642T DK3111950T3 DK 3111950 T3 DK3111950 T3 DK 3111950T3 DK 16183642 T DK16183642 T DK 16183642T DK 3111950 T3 DK3111950 T3 DK 3111950T3
Authority
DK
Denmark
Prior art keywords
methods
prostate cancer
glucocorticoid receptor
receptor antagonism
compositions related
Prior art date
Application number
DK16183642.4T
Other languages
English (en)
Inventor
Russell Z Szmulewitz
Suzanne D Conzen
Original Assignee
Univ Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Chicago filed Critical Univ Chicago
Application granted granted Critical
Publication of DK3111950T3 publication Critical patent/DK3111950T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK16183642.4T 2012-02-24 2013-02-21 Fremgangsmåder og sammensætninger relateret til glucocorticoidreceptorantagonisme og prostatacancer DK3111950T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261603137P 2012-02-24 2012-02-24
EP13751132.5A EP2817019A4 (en) 2012-02-24 2013-02-21 METHODS AND COMPOSITIONS ASSOCIATED WITH GLUCOCORTICOID RECEPTOR ANTAGONISM AND PROSTATE CANCER

Publications (1)

Publication Number Publication Date
DK3111950T3 true DK3111950T3 (da) 2021-10-04

Family

ID=49006202

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16183642.4T DK3111950T3 (da) 2012-02-24 2013-02-21 Fremgangsmåder og sammensætninger relateret til glucocorticoidreceptorantagonisme og prostatacancer

Country Status (7)

Country Link
US (6) US9289436B2 (da)
EP (3) EP3912626B1 (da)
DK (1) DK3111950T3 (da)
ES (1) ES2888425T3 (da)
PL (1) PL3111950T3 (da)
PT (1) PT3111950T (da)
WO (1) WO2013126581A1 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3111950T3 (da) 2012-02-24 2021-10-04 Univ Chicago Fremgangsmåder og sammensætninger relateret til glucocorticoidreceptorantagonisme og prostatacancer
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
EP3777845A1 (en) 2012-09-26 2021-02-17 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
WO2015089338A2 (en) * 2013-12-11 2015-06-18 Sloan-Kettering Institute For Cancer Research Glucocorticoid inhibitors for treatment of prostate cancer
EP3079771A4 (en) * 2013-12-11 2018-01-10 Sloan-kettering Institute For Cancer Research Sgk1 inhibitors for treatment of prostate cancer
WO2015089402A1 (en) 2013-12-12 2015-06-18 The University Of Chicago Methods and compositions related to hsp90 inhibitors and breast cancer
WO2016162229A1 (en) 2015-04-10 2016-10-13 Capsugel Belgium N.V. Abiraterone acetate lipid formulations
WO2017091574A1 (en) * 2015-11-25 2017-06-01 Health Research, Inc. Riluzole and riluzole drug combinations for the treatment of prostate cancer
CA3009522A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
US11110103B2 (en) 2015-12-23 2021-09-07 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
CA3009525A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
GB201609193D0 (en) * 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
US20190134004A1 (en) * 2016-06-16 2019-05-09 The University Of Chicago Methods and compositions for treating breast and prostate cancer
EP3503898A1 (en) 2016-08-29 2019-07-03 California Institute of Technology Compositions and methods for treatment of prostate cancer
US9943505B2 (en) 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
MX2019004030A (es) 2016-10-07 2019-09-16 Oric Pharmaceuticals Inc Inhibidores del receptor de glucocorticoides.
CN110072529B (zh) * 2016-10-14 2022-11-22 济州大学校产学协力团 包含环索奈德的用于抑制癌症干细胞的生长的组合物
CN110520121B (zh) 2017-03-31 2023-07-04 科赛普特治疗学股份有限公司 糖皮质激素受体调节剂治疗宫颈癌
WO2018236749A2 (en) * 2017-06-20 2018-12-27 Corcept Therapeutics, Inc. METHODS OF TREATING NEURO-EPITHELIAL TUMORS USING GLUCOCORTICOID RECEPTOR SELECTIVE MODULATORS
WO2019078920A1 (en) 2017-10-16 2019-04-25 Aragon Pharmaceuticals, Inc. ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC RESISTANT PROSTATE CANCER
EP3480201A1 (en) 2017-11-06 2019-05-08 Oncostellae, S.L. New analogs as androgen receptor and glucocorticoid receptor modulators
US11299786B2 (en) 2018-07-05 2022-04-12 Rutgers, The State University Of New Jersey Gene panel to predict response to androgen deprivation in prostate cancer
CA3121193C (en) 2018-12-19 2024-03-12 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
WO2020132046A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
WO2020172501A1 (en) 2019-02-22 2020-08-27 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
US12133846B2 (en) 2019-10-15 2024-11-05 Wayne State University Electrophilic androgen receptor (AR) antagonists for AR downregulation and ferroptosis induction in cancer cells
CA3166901A1 (en) * 2020-02-10 2021-08-19 Corcept Therapeutics Incorporated Methods of stimulating an anti-tumor response using a selective glucocorticoid receptor modulator
WO2022104258A1 (en) * 2020-11-16 2022-05-19 Ambay Immune Sensors And Controls, Llc/Ambay Compositions and methods for identification, assessment and treatment of cancer patient
US20240058349A1 (en) * 2020-12-18 2024-02-22 Northwestern University Pi3k inhibitors for protection against glucocorticoid-induced atrophy
WO2023183843A1 (en) * 2022-03-23 2023-09-28 Purdue Research Foundation Combination therapy for treating castration-resistant prostate cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005082935A1 (en) * 2004-02-26 2005-09-09 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Stamp modulation of glucocorticoid-responsive gene expression
US20120022121A1 (en) * 2007-11-29 2012-01-26 Dalton James T Indoles, derivatives and analogs thereof and uses therefor
US20090156672A1 (en) * 2007-12-17 2009-06-18 Northwestern University Substituted Phenyl Aziridine Precursor Analogs as Modulators of Steroid Receptor Activities
US8710035B2 (en) 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
US9314473B2 (en) * 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
JP5804395B2 (ja) 2011-02-03 2015-11-04 ポップ テスト オンコロジー エルエルシー 診断と治療のためのシステムおよび方法
DK3111950T3 (da) 2012-02-24 2021-10-04 Univ Chicago Fremgangsmåder og sammensætninger relateret til glucocorticoidreceptorantagonisme og prostatacancer
WO2023088358A1 (en) * 2021-11-17 2023-05-25 Chengdu Anticancer Bioscience, Ltd. Treatment of cancer with a glucocorticoid receptor agonist and an hiv protease inhibitor

Also Published As

Publication number Publication date
US20190255069A1 (en) 2019-08-22
EP3912626A1 (en) 2021-11-24
US20180036318A1 (en) 2018-02-08
PT3111950T (pt) 2021-10-19
US10729699B2 (en) 2020-08-04
EP2817019A1 (en) 2014-12-31
US10300076B2 (en) 2019-05-28
EP3111950A1 (en) 2017-01-04
PL3111950T3 (pl) 2022-01-17
EP3111950B1 (en) 2021-08-25
US11564932B2 (en) 2023-01-31
US9289436B2 (en) 2016-03-22
US20150010503A1 (en) 2015-01-08
US20160151388A1 (en) 2016-06-02
US20200330482A1 (en) 2020-10-22
ES2888425T3 (es) 2022-01-04
US20230218634A1 (en) 2023-07-13
US9801893B2 (en) 2017-10-31
EP2817019A4 (en) 2016-04-06
EP3912626B1 (en) 2024-08-21
WO2013126581A1 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
DK3111950T3 (da) Fremgangsmåder og sammensætninger relateret til glucocorticoidreceptorantagonisme og prostatacancer
DK2929031T5 (da) Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
DK2877599T3 (da) Fremgangsmåder og sammensætninger til bestemmelse af resistens overfor androgenreceptorterapi
IL271305B (en) Anti-ntb–a antibodies and related compositions and methods
DK3421051T3 (da) Fremgangsmåder til glycokonjugering og sammensætninger
HK1214630A1 (zh) 響應於抗癌療法的腫瘤細胞標誌物
DK2872153T3 (da) Accellulære pro-tolerogene sammensætninger og fremgangsmåde til fremstilling heraf
EP2895559A4 (en) BITUMEN COMPOSITIONS AND METHODS OF MAKING
DK2857401T3 (da) Hidtil ukendt -lactamaseinhibitor og fremgangsmåde til at fremstille samme
DK2844292T3 (da) ST2L-antagonister og fremgangsmåder til anvendelse
BR112014020543A2 (pt) composições de ração e métodos de utilização das mesmas
DK2861223T3 (da) Sammensætninger og metoder til transmukosal absorption
DK2877019T3 (da) Sikkerede herbisidiske sammensætninger til anvendelse i ris
HK1212251A1 (en) Topical compositions and methods of use
EP3186393A4 (en) Methods and compositions related to prostate cancer therapeutics
EP2884984A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD
DK2908661T3 (da) Mikroalgemelgranulater og fremgangsmåde til fremstilling deraf
SG11201602258WA (en) Slow-release conjugates of sn-38
DK2854822T3 (da) Polysaccharidsammensætninger og fremgangsmåder til anvendelse
DK3175852T3 (da) Difluorlactamsammensætninger til EP4-medierede osteorelaterede sygdomme og tilstande
IL232466A0 (en) Preparations and methods for the analysis of prostate cancer
GB201314485D0 (en) Materials and methods relating to pancreatic cancer
DK2849798T3 (da) Oligonukleotid-chelatkompleks-polypeptidsammensætninger og fremgangsmåder
EP2895186A4 (en) THERAPEUTIC COMPOSITIONS AND RELATED METHODS
DK3010552T3 (da) Sammensætninger til anvendelse i onkologi